The World Health Organization (WHO) adopted the eleventh revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-11) at its World Health Assembly meeting in May 2019. It addition to other major changes, ICD-11 includes a new classification for chronic pain as well as new groups of codes for chronic pain conditions. After a decade of preparation, ICD-11 will become effective in January 2022. The advance release allows countries to plan how to use the new version and train health professionals.
The AAPM 2020 Annual Meeting Program Committee is now accepting educational session proposals through July 15, 5 pm CT . The AAPM Annual Meeting is the must-attend meeting of the year for clinicians treating patients in ...
Bring awareness and recognition of headache disorder as a legitimate neurobiological disease and help make individuals with headache disorder know that there are new treatments available. Read about the AAPM Foundation's...
Five fundamental treatment goals of a pain psychologist are reviewed in the Psychology Today blog post. Full story.
Repetitive transcranial magnetic stimulation (rTMS), a non-invasive brain stimulation technique, may be a viable therapy for women with endometriosis experiencing chronic pelvic pain for whom other treatments have failed...
Individuals with versus without cluster headache were found to have lower cranial and extracranial pressure pain thresholds, indicating central sensitization, according to a study published in Pain Medicine . Full story....
In a study published in Science , a team assessed the responses of eight kinds of mole-rats and two other rodent species to three substances that normally elicit pain: acid, capsaicin, and allyl isothiocyanate (AITC), th...
Integrative medicine services — primarily massage therapy — resulted in a significant reduction in pain among hospitalized patients, according to recent research at two Mayo Clinic hospitals. Full story.
Eli Lilly and Company announced a license agreement to acquire the exclusive worldwide rights for CNTX-0290 from Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapeutics for the treatment of chronic pain. CNTX-0290, is a novel, small molecule somatostatin receptor type 4 (SSTR4) agonist that is currently being studied in Phase 1 clinical testing as a potential non-opioid treatment for chronic pain conditions.
Peripheral electrical stimulation (PES), which encompasses several techniques with heterogeneous physiological responses, has shown in some cases remarkable outcomes for pain treatment and clinical rehabilitation. Howeve...